228 related articles for article (PubMed ID: 31408923)
1. Genetic risk association of CDKN1A and RET gene SNPs with medullary thyroid carcinoma: Results from the largest MTC cohort and meta-analysis.
Mishra V; Kowtal P; Rane P; Sarin R
Cancer Med; 2019 Oct; 8(13):6151-6161. PubMed ID: 31408923
[TBL] [Abstract][Full Text] [Related]
2. Modulatory Role of Single Nucleotide Polymorphisms of Distinct Genetic Pathways on Clinical Behavior of Medullary Thyroid Carcinoma.
Mishra V; Kowtal P; Rane P; Sarin R
Asian Pac J Cancer Prev; 2020 May; 21(5):1289-1293. PubMed ID: 32458635
[TBL] [Abstract][Full Text] [Related]
3. Additive effect of RET polymorphisms on sporadic medullary thyroid carcinoma susceptibility and tumor aggressiveness.
Ceolin L; Siqueira DR; Ferreira CV; Romitti M; Maia SC; Leiria L; Crispim D; Ashton-Prolla P; Maia AL
Eur J Endocrinol; 2012 May; 166(5):847-54. PubMed ID: 22345297
[TBL] [Abstract][Full Text] [Related]
4. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
[TBL] [Abstract][Full Text] [Related]
5. Quantitative assessment of the association between L769L and S836S polymorphisms at RET gene and medullary thyroid carcinoma risk.
Zhang Y; Wang S; Chen X; Huang S; Li J
Tumour Biol; 2014 Jul; 35(7):6641-7. PubMed ID: 24699996
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma?
Baumgartner-Parzer SM; Lang R; Wagner L; Heinze G; Niederle B; Kaserer K; Waldhäusl W; Vierhapper H
J Clin Endocrinol Metab; 2005 Nov; 90(11):6232-6. PubMed ID: 16118333
[TBL] [Abstract][Full Text] [Related]
7. Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary/papillary thyroid carcinomas in 2 large, non-related families with the RET V804M proto-oncogene mutation.
Shifrin AL; Ogilvie JB; Stang MT; Fay AM; Kuo YH; Matulewicz T; Xenachis CZ; Vernick JJ
Surgery; 2010 Dec; 148(6):1274-80; discussion 1280-1. PubMed ID: 21134561
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms Within the
Gemignani F; Romei C; Ciampi R; Corrado A; Melaiu O; Figlioli G; Bonotti A; Foddis R; Cristaudo A; Pellegrini G; Vivaldi A; Cipollini M; Landi S; Elisei R
Thyroid; 2020 Nov; 30(11):1579-1588. PubMed ID: 32228166
[No Abstract] [Full Text] [Related]
9. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
[TBL] [Abstract][Full Text] [Related]
10. The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma.
Weinhaeusel A; Scheuba C; Lauss M; Kriegner A; Kaserer K; Vierlinger K; Haas OA; Niederle B
Thyroid; 2008 Dec; 18(12):1269-76. PubMed ID: 18976163
[TBL] [Abstract][Full Text] [Related]
11. p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low Lifetime Risk of Medullary Thyroid Cancer.
Loveday C; Josephs K; Chubb D; Gunning A; Izatt L; Tischkowitz M; Ellard S; Turnbull C
J Clin Endocrinol Metab; 2018 Nov; 103(11):4275-4282. PubMed ID: 29590403
[TBL] [Abstract][Full Text] [Related]
12. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.
Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM
BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802
[TBL] [Abstract][Full Text] [Related]
13. Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form.
Figlioli G; Landi S; Romei C; Elisei R; Gemignani F
Mutat Res; 2013; 752(1):36-44. PubMed ID: 23059849
[TBL] [Abstract][Full Text] [Related]
14. The frequency of selected polymorphic variants of the RET gene in patients with medullary thyroid carcinoma and in the general population of central Poland.
Sromek M; Czetwertyńska M; Skasko E; Zielińska J; Czapczak D; Steffen J
Endocr Pathol; 2010 Sep; 21(3):178-85. PubMed ID: 20521125
[TBL] [Abstract][Full Text] [Related]
15. Utilization of Genetic Testing for RET Mutations in Patients with Medullary Thyroid Carcinoma: a Single-Center Experience.
Parkhurst E; Calonico E; Abboy S
J Genet Couns; 2018 Dec; 27(6):1411-1416. PubMed ID: 29951718
[TBL] [Abstract][Full Text] [Related]
16. The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.
Oczko-Wojciechowska M; Pfeifer A; Rusinek D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Kowal M; Swierniak M; Krajewska J; Gawlik T; Chmielik E; Czarniecka A; Szpak-Ulczok S; Jarząb B
Endokrynol Pol; 2015; 66(2):121-5. PubMed ID: 25931041
[TBL] [Abstract][Full Text] [Related]
17. The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma.
Siqueira DR; Romitti M; da Rocha AP; Ceolin L; Meotti C; Estivalet A; Puñales MK; Maia AL
Endocr Relat Cancer; 2010 Dec; 17(4):953-63. PubMed ID: 20801952
[TBL] [Abstract][Full Text] [Related]
18. A pioneering RET genetic screening study in the State of Ceará, Brazil, evaluating patients with medullary thyroid cancer and at-risk relatives: experience with 247 individuals.
Martins-Costa MC; Lindsey SC; Cunha LL; Carreiro-Filho FP; Cortez AP; Holanda ME; Farias JWM; Lima SB; Ferreira LAA; Maia Filho PC; Camacho CP; Furuzawa GK; Kunii IS; Dias-da-Silva MR; Martins JRM; Maciel RMB
Arch Endocrinol Metab; 2018; 62(6):623-635. PubMed ID: 30624503
[TBL] [Abstract][Full Text] [Related]
19. Significance of the RET proto-oncogene polymorphisms in Turkish sporadic medullary thyroid carcinoma patients.
Gursoy A; Erdogan MF; Erdogan G
J Endocrinol Invest; 2006 Nov; 29(10):858-62. PubMed ID: 17185892
[TBL] [Abstract][Full Text] [Related]
20. Search of the p.M918T Mutation in the RET Oncogene in Mexican Adult Patients with Medullary Thyroid Carcinoma.
Ruiz-Garcia E; Vidal-Millan S; Lopez-Yañez A; Torres JAP; Guadarrama-Orozco JA; Lino-Silva LS; Meneses-Garcia A; Astudillo-de la Vega H; Garcia MG
Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):218-222. PubMed ID: 28166591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
